118 related articles for article (PubMed ID: 9280370)
1. Pharmacology of the 5-lipoxygenase inhibitors BAY Y 1015 and BAY X 1005 in the horse.
Cunningham FM; Andrews M; Landoni MF; Lees P
J Vet Pharmacol Ther; 1997 Aug; 20(4):296-307. PubMed ID: 9280370
[TBL] [Abstract][Full Text] [Related]
2. Ionophore A23187-induced leukotriene biosynthesis in equine granulocytes-neutrophils, but not eosinophils require exogenous arachidonic acid.
Lindberg A; Tornhamre S; Mugnai S; Lindgren J
Biochim Biophys Acta; 1998 Mar; 1391(2):247-55. PubMed ID: 9555040
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of leukotriene C4 and B4 release by human eosinophils with the new 5-lipoxygenase inhibitor 6-hydroxy-2(4-sulfamoylbenzylamino)-4,5,7-trimethylbenzothiazo le hydrochloride.
Fukuda T; Numao T; Akutsu I; Toda M; Motojima S; Makino S
Arzneimittelforschung; 1995 Sep; 45(9):1002-4. PubMed ID: 7488299
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of leukotriene C4 and B4 generation by human eosinophils and neutrophils with the lipoxygenase pathway inhibitors U60257 and BW755C.
Cromwell O; Shaw RJ; Walsh GM; Mallet AI; Kay AB
Int J Immunopharmacol; 1985; 7(5):775-81. PubMed ID: 2995265
[TBL] [Abstract][Full Text] [Related]
5. Ca2+ ionophore A23187-stimulated secretion of azurophil granules in human polymorphonuclear leukocytes is largely mediated by endogenously formed leukotriene B4.
Hatzelmann A; Fruchtmann R; Mohrs KH; Raddatz S; Müller-Peddinghaus R
Biochem Pharmacol; 1994 Jul; 48(1):31-9. PubMed ID: 8043028
[TBL] [Abstract][Full Text] [Related]
6. In vitro pharmacology of BAY X1005, a new inhibitor of leukotriene synthesis.
Fruchtmann R; Mohrs KH; Hatzelmann A; Raddatz S; Fugmann B; Junge B; Horstmann H; Müller-Peddinghaus R
Agents Actions; 1993 Mar; 38(3-4):188-95. PubMed ID: 8213345
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of fenleuton, a 5-lipoxygenase inhibitor, in ponies.
Marr K; Marsh K; Hernandez L; Cunningham FM; Lees P
Res Vet Sci; 1998; 64(2):111-7. PubMed ID: 9625466
[TBL] [Abstract][Full Text] [Related]
8. The effect of leukotriene synthesis inhibitors in models of acute and chronic inflammation.
Nickerson-Nutter CL; Medvedeff ED
Arthritis Rheum; 1996 Mar; 39(3):515-21. PubMed ID: 8607901
[TBL] [Abstract][Full Text] [Related]
9. Enhancement by monokines of leukotriene generation by human eosinophils and neutrophils stimulated with calcium ionophore A23187.
Dessein AJ; Lee TH; Elsas P; Ravalese J; Silberstein D; David JR; Austen KF; Lewis RA
J Immunol; 1986 May; 136(10):3829-38. PubMed ID: 3009610
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of equine mononuclear cell proliferation and leukotriene B4 synthesis by a specific 5-lipoxygenase inhibitor, A-63162.
Olsen SC; Atluru D; Atluru S; McVey DS; Erickson HH
Am J Vet Res; 1992 Jun; 53(6):1015-8. PubMed ID: 1320811
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological modulation of human platelet leukotriene C4-synthase.
Sala A; Folco G; Henson PM; Murphy RC
Biochem Pharmacol; 1997 Mar; 53(6):905-8. PubMed ID: 9113110
[TBL] [Abstract][Full Text] [Related]
12. Nedocromil sodium inhibits the A23187- and opsonized zymosan-induced leukotriene formation by human eosinophils but not by human neutrophils.
Bruijnzeel PL; Hamelink ML; Kok PT; Kreukniet J
Br J Pharmacol; 1989 Mar; 96(3):631-6. PubMed ID: 2541846
[TBL] [Abstract][Full Text] [Related]
13. Methoxytetrahydropyrans. A new series of selective and orally potent 5-lipoxygenase inhibitors.
Crawley GC; Dowell RI; Edwards PN; Foster SJ; McMillan RM; Walker ER; Waterson D; Bird TG; Bruneau P; Giroaeau JM
J Med Chem; 1992 Jul; 35(14):2600-9. PubMed ID: 1321908
[TBL] [Abstract][Full Text] [Related]
14. Assessment of the in vivo biochemical efficacy of orally active leukotriene biosynthesis inhibitors.
Tagari P; Brideau C; Chan C; Frenette R; Black C; Ford-Hutchinson A
Agents Actions; 1993 Sep; 40(1-2):62-71. PubMed ID: 8147271
[TBL] [Abstract][Full Text] [Related]
15. Mode of action of the new selective leukotriene synthesis inhibitor BAY X 1005 ((R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl acetic acid) and structurally related compounds.
Hatzelmann A; Fruchtmann R; Mohrs KH; Raddatz S; Müller-Peddinghaus R
Biochem Pharmacol; 1993 Jan; 45(1):101-11. PubMed ID: 8381000
[TBL] [Abstract][Full Text] [Related]
16. Pre-clinical pharmacology of ICI D2138, a potent orally-active non-redox inhibitor of 5-lipoxygenase.
McMillan RM; Spruce KE; Crawley GC; Walker ER; Foster SJ
Br J Pharmacol; 1992 Dec; 107(4):1042-7. PubMed ID: 1334748
[TBL] [Abstract][Full Text] [Related]
17. BAY X1005, a new selective inhibitor of leukotriene synthesis: pharmacology and pharmacokinetics.
Müller-Peddinghaus R; Fruchtmann R; Ahr HJ; Beckermann B; Bühner K; Fugmann B; Junge B; Matzke M; Kohlsdorfer C; Raddatz S
J Lipid Mediat; 1993; 6(1-3):245-8. PubMed ID: 8395246
[TBL] [Abstract][Full Text] [Related]
18. Characterization of leukotriene B4 synthesis in canine polymorphonuclear leukocytes.
Amalsadvala TM; Vaughn DM
Prostaglandins Leukot Essent Fatty Acids; 1992 Apr; 45(4):283-8. PubMed ID: 1318548
[TBL] [Abstract][Full Text] [Related]
19. Generation and metabolism of 5-lipoxygenase pathway leukotrienes by human eosinophils: predominant production of leukotriene C4.
Weller PF; Lee CW; Foster DW; Corey EJ; Austen KF; Lewis RA
Proc Natl Acad Sci U S A; 1983 Dec; 80(24):7626-30. PubMed ID: 6324182
[TBL] [Abstract][Full Text] [Related]
20. Selective inhibition of arachidonate 5-lipoxygenase by novel acetohydroxamic acids: biochemical assessment in vitro and ex vivo.
Tateson JE; Randall RW; Reynolds CH; Jackson WP; Bhattacherjee P; Salmon JA; Garland LG
Br J Pharmacol; 1988 Jun; 94(2):528-39. PubMed ID: 2840160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
